CoChat

Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical outcomes prior to anti-PD(L)-1 inhibition monotherapy (IO) has been demonstrated in multiple studies, but the impact of antibiotic exposure prior to initiation of Chemo-IO is controversial. We assessed antibiotic exposures at two time windows: within 60 days prior to therapy (-60 d window) and within 60 days prior to therapy and 42 days after therapy (-60 + 42d window) in 2028 patients with advanced NSCLC treated with Chemo-IO and IO monotherapy focusing on objective response rate (ORR: rate of partial response and complete response), progression-free survival (PFS), and overall survival (OS). We also assessed impact of antibiotic exposure in an independent cohort of 53 patients. Univariable and multivariable analyses were conducted along with a meta-analysis from similar studies. For the -60 d window, in the Chemo-IO group (N = 769), 183 (24%) patients received antibiotics. Antibiotic exposure was associated with worse ORR (27% vs 40%, p = 0.001), shorter PFS (3.9 months vs. 5.9 months, hazard ratio [HR] 1.35, 95%CI 1.1,1.6, p = 0.0012), as well as shorter OS (10 months vs. 15 months, HR 1.50, 95%CI 1.2,1.8, p = 0.00014). After adjusting for known prognostic factors in NSCLC, antibiotic exposure was independently associated with worse PFS (HR 1.39, 95%CI 1.35,1.7, p = 0.002) and OS (HR 1.61, 95%CI 1.28,2.03, p < 0.001). Similar results were obtained in the -60 + 42d window, and also in an independent cohort. In a meta-analysis of patients with NSCLC treated with Chemo-IO (N = 4) or IO monotherapy (N = 13 studies) antibiotic exposure before treatment was associated with worse OS among all patients (n = 11,351) (HR 1.93, 95% CI 1.52, 2.45) and Chemo-IO-treated patients (n = 1201) (HR 1.54, 95% CI 1.28, 1.84). Thus, antibiotics exposure prior to Chemo-IO is common and associated with worse outcomes, even after adjusting for other factors. These results highlight the need to implement antibiotic stewardship in routine oncology practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-024-00630-w

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Association between antibiotic exposure and outcomes to combination platinum-doublet chemotherapy and immunotherapy in patients with non-small cell lung cancer. A Objective response rate, B Progression-free survival, C Overall survival in antibiotics vs. no antibiotics group. D Multivariable cox model for PFS and (E). OS for antibiotics vs. no antibiotics while adjusting for standard prognostic features in non-small cell lung cancer. mPFS, median progression-free survival; mOS, median overall survival; HR, hazard ratio; 95%CI, 95% confidence interval. Median survival times given and numbers in parentheses represent 95% confidence intervals.
Fig. 1 Association between antibiotic exposure and outcomes to combination platinum-doublet chemotherapy and immunotherapy in patients with non-small cell lung cancer. A Objective response rate, B Progression-free survival, C Overall survival in antibiotics vs. no antibiotics group. D Multivariable cox model for PFS and (E). OS for antibiotics vs. no antibiotics while adjusting for standard prognostic features in non-small cell lung cancer. mPFS, median progression-free survival; mOS, median overall survival; HR, hazard ratio; 95%CI, 95% confidence interval. Median survival times given and numbers in parentheses represent 95% confidence intervals.CC BY · PubMed Central
Fig. 2 Association between antibiotic exposure and outcomes to immunotherapy alone in patients with non-small cell lung cancer. A Objective response rate, B Progression-free survival, C Overall survival in antibiotics vs. no antibiotics group. D Multivariable cox model for PFS and (E). OS for antibiotics vs. no antibiotics while adjusting for standard prognostic features in non-small cell lung cancer. mPFS, median progression-free survival; mOS, median overall survival; HR, hazard ratio; 95%CI, 95% confidence interval. Median survival times given and numbers in parentheses represent 95% confidence intervals.
Fig. 2 Association between antibiotic exposure and outcomes to immunotherapy alone in patients with non-small cell lung cancer. A Objective response rate, B Progression-free survival, C Overall survival in antibiotics vs. no antibiotics group. D Multivariable cox model for PFS and (E). OS for antibiotics vs. no antibiotics while adjusting for standard prognostic features in non-small cell lung cancer. mPFS, median progression-free survival; mOS, median overall survival; HR, hazard ratio; 95%CI, 95% confidence interval. Median survival times given and numbers in parentheses represent 95% confidence intervals.CC BY · PubMed Central
Fig. 3 Meta-analysis of all studies examining the association of antibiotic exposure on overall survival to Immunotherapy (IO) alone or platinum doublet Chemo-IO in non-small cell lung cancer; strictly before initiation of IO or Chemo-IO. A literature review described in the Methods was performed to gather all available retrospective and prospective clinical studies evaluating the association between antibiotic exposure and outcome to either IO alone or Chemo-IO. Each included study is listed by row, with hazard ratios (HRs), study weightings (inverse variance), the total number of patients and the subset of antibiotic (ATB)-exposed patients denoted. RE model with representation of the p-value for heterogeneity between studies, random effects model; df, degrees of freedom. A For Chemo-IO and IO studies; B For Chemo-IO studies.
Fig. 3 Meta-analysis of all studies examining the association of antibiotic exposure on overall survival to Immunotherapy (IO) alone or platinum doublet Chemo-IO in non-small cell lung cancer; strictly before initiation of IO or Chemo-IO. A literature review described in the Methods was performed to gather all available retrospective and prospective clinical studies evaluating the association between antibiotic exposure and outcome to either IO alone or Chemo-IO. Each included study is listed by row, with hazard ratios (HRs), study weightings (inverse variance), the total number of patients and the subset of antibiotic (ATB)-exposed patients denoted. RE model with representation of the p-value for heterogeneity between studies, random effects model; df, degrees of freedom. A For Chemo-IO and IO studies; B For Chemo-IO studies.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 68

Metadata

Authors
Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., Zitvogel, L., Rudin, C. M., Routy, B., Derosa, L., & Schoenfeld, A. J.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Inserm (FR)
Corresponding author
  • Elkrief, Arielle
  • Schoenfeld, Adam J.
Venue
npj Precision Oncology
Published
2024-07-16
Volume
8
Issue
1
Pages
143-143
ISSN
2397-768X (ISSN-L)
OpenAlex
W4400677411
Cited by
68
References
35
Citations by year
2026: 36 · 2025: 30 · 2024: 2
FWCI
11.64
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Precision Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Damon Runyon Cancer Research Foundation (P30 CA008748, CI-98-18)
  • Memorial Sloan-Kettering Cancer Center (CA008748, P30 CA008748)
  • Cancer Research Society
  • Parker Institute for Cancer Immunotherapy
  • Royal College of Physicians and Surgeons of Canada
  • Agence Nationale de la Recherche (ANR-21-RHUS-0017)
  • Canadian Institutes of Health Research
  • National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
antibiotics, non-small cell lung cancer, immune checkpoint inhibitors, anti-PD-1 therapy, platinum-based chemotherapy, chemoimmunotherapy, objective response rate, progression-free survival, overall survival, prognostic factors, immune-related adverse events

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. https://app.cochat.ai/papers/10.1038/s41698-024-00630-w
The paper
Elkrief, A., Méndez-Salazar, E. O., Maillou, J., Vanderbilt, C. M., Gogia, P., Desilets, A., Messaoudene, M., Kelly, D., Ladanyi, M., Hellmann, M. D., Zitvogel, L., Rudin, C. M., Routy, B., Derosa, L., & Schoenfeld, A. J. (2024). Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy. npj Precision Oncology. https://doi.org/10.1038/s41698-024-00630-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.